Risk Factors Update Summary
- Addition of risk related to inconclusive clinical trials, safety concerns, and adverse events for product candidates.
- Mention of potential failure to achieve benefits from strategic pipeline prioritization and restructuring plan.
- Increase in revenue concentration with one customer accounting for 95% of total revenues in 2023.
- Disclosure of cybersecurity incidents and risks, including social engineering, ransomware, and data breaches.
- Uncertainty regarding the outcome of patent litigation with Sarepta Therapeutics, Inc.
- Risk related to fluctuations in operating results impacting the ability to raise capital through equity securities.
- Potential adverse effects if patents covering the NAV Technology Platform are subject to compulsory licensing laws.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1590877&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.